The BodyBuilders have written a fresh article on AOD9604 Patent process, well worth a read, some key quotes are contained below:
http://musculardevelopmentmag.com.au/shane-charter-muscular-mythbusters/
You could be excused for thinking that peptides were a new innovation in the sports supplement market. The media saturation surrounding the cases made by multiple professional sporting bodies’ against players, and the Australian Crime Commission’s report into drugs in sport has portrayed an image of this new age scourge entering the sporting arena.
The fact is I was using my first peptides in sport over 20 years ago and have continued to do so since that first competition. The first peptide I used was IGF-1 lr3 and only due to my pharmaceutical industry job was I able to access such an innovative product back then.
Even then peptides had already been around for 10 years. It was 1984 when the first chemically synthesised peptide drug was launched. It was a luteinising hormone releasing hormone (LHRH). Today there are over 60 therapeutic-based peptides available on the medical market and hundreds of non-proven peptide entities marketed online, with many claims but not the clinical data to obtain a medical listing.
The market value exceeds $20 Billion USD per annum and it is one of the fastest growing segments of the health care market, with peptides providing some therapeutic solutions for diseases such as HIV, diabetes, cancer, hepatitis, sexual dysfunction, hepatitis, obesity and even wrinkle treatments. It is the innovative biochemist/bodybuilder that then looks at a medical therapeutic benefit and thinks of how it can be applied to building a better body.
This may be muscle building, fat burning, tendon and ligament strengthening or even for sexual improvements that could assist when the testicles have shut down
Let’s use AOD (Anti Obesity Drug) 9604 as a discussion peptide to get my point across of how difficult it is for the consumer to establish if a peptide is myth or magic.
The reason I am using this example is because ever since a high profile footballer came out and said he was injected with AOD-9604, I have had hundreds of emails enquiring about the efficacy and suitability of AOD for other people’s programs.
Metabolic Pharmaceuticals, the manufacturers and patent holders of AOD-9604 had effectively shelved the product after spending $50 million in development, saying that it would not be a viable entrant into the market.
The peptide was proven to be safe and well tolerated in a total of six human clinical trials involving 925 humans, and the preliminary work in test tubes showed that the peptide may stimulate the growth of bones, muscle and cartilage cells. This then led to massive funding and a trial in animals.
A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis or fat burning.
The next phase was to run human clinical trials. These trials however, had no positive outcome for the peptide; in fact when follow up trials were done in rats, they were unable to replicate the positive results of the obese mice from the first trial.
In 2007, the company that owns Metabolic Pharmaceuticals, Calzada, reported to their shareholders that AOD-9604 showed no promise, and was being abandoned as a weight loss drug. The peptide was shelved, until the company heard that athletes were using it based on the early work in obese mice. They found that there was a growing market for their patented product. So rather than try to sue the Chinese companies that were illegally copying their patented peptide, they decided to get their own version onto the market.
Calzada, the parent company of Metabolic Pharmaceuticals said in a statement in
June 2012: “Generally Recognised As Safe (GRAS) status allows AOD-9604 to be sold as a nutrient supplement in conventional and functional foods, drinks and dietary supplements in the USA at the daily level of up to 1mg per person.”
The doses used in trials were around 500ug/kg, which means a 100kg person was receiving 50mg of the peptide daily.
Irrespective of dose, the company themselves have previously stated that AOD-9604 is not effective orally. So potentially, the injected form may have some benefits but this has not been approved.
While AOD-9604 is not approved by the Australian Therapeutic Goods Administration (TGA), it can be legally obtained on a doctor’s prescription and dispensed by a compounding pharmacy.
http://musculardevelopmentmag.com.au/shane-charter-muscular-mythbusters/
You could be excused for thinking that peptides were a new innovation in the sports supplement market. The media saturation surrounding the cases made by multiple professional sporting bodies’ against players, and the Australian Crime Commission’s report into drugs in sport has portrayed an image of this new age scourge entering the sporting arena.
The fact is I was using my first peptides in sport over 20 years ago and have continued to do so since that first competition. The first peptide I used was IGF-1 lr3 and only due to my pharmaceutical industry job was I able to access such an innovative product back then.
Even then peptides had already been around for 10 years. It was 1984 when the first chemically synthesised peptide drug was launched. It was a luteinising hormone releasing hormone (LHRH). Today there are over 60 therapeutic-based peptides available on the medical market and hundreds of non-proven peptide entities marketed online, with many claims but not the clinical data to obtain a medical listing.
The market value exceeds $20 Billion USD per annum and it is one of the fastest growing segments of the health care market, with peptides providing some therapeutic solutions for diseases such as HIV, diabetes, cancer, hepatitis, sexual dysfunction, hepatitis, obesity and even wrinkle treatments. It is the innovative biochemist/bodybuilder that then looks at a medical therapeutic benefit and thinks of how it can be applied to building a better body.
This may be muscle building, fat burning, tendon and ligament strengthening or even for sexual improvements that could assist when the testicles have shut down
Let’s use AOD (Anti Obesity Drug) 9604 as a discussion peptide to get my point across of how difficult it is for the consumer to establish if a peptide is myth or magic.
The reason I am using this example is because ever since a high profile footballer came out and said he was injected with AOD-9604, I have had hundreds of emails enquiring about the efficacy and suitability of AOD for other people’s programs.
Metabolic Pharmaceuticals, the manufacturers and patent holders of AOD-9604 had effectively shelved the product after spending $50 million in development, saying that it would not be a viable entrant into the market.
The peptide was proven to be safe and well tolerated in a total of six human clinical trials involving 925 humans, and the preliminary work in test tubes showed that the peptide may stimulate the growth of bones, muscle and cartilage cells. This then led to massive funding and a trial in animals.
A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis or fat burning.
The next phase was to run human clinical trials. These trials however, had no positive outcome for the peptide; in fact when follow up trials were done in rats, they were unable to replicate the positive results of the obese mice from the first trial.
In 2007, the company that owns Metabolic Pharmaceuticals, Calzada, reported to their shareholders that AOD-9604 showed no promise, and was being abandoned as a weight loss drug. The peptide was shelved, until the company heard that athletes were using it based on the early work in obese mice. They found that there was a growing market for their patented product. So rather than try to sue the Chinese companies that were illegally copying their patented peptide, they decided to get their own version onto the market.
Calzada, the parent company of Metabolic Pharmaceuticals said in a statement in
June 2012: “Generally Recognised As Safe (GRAS) status allows AOD-9604 to be sold as a nutrient supplement in conventional and functional foods, drinks and dietary supplements in the USA at the daily level of up to 1mg per person.”
The doses used in trials were around 500ug/kg, which means a 100kg person was receiving 50mg of the peptide daily.
Irrespective of dose, the company themselves have previously stated that AOD-9604 is not effective orally. So potentially, the injected form may have some benefits but this has not been approved.
While AOD-9604 is not approved by the Australian Therapeutic Goods Administration (TGA), it can be legally obtained on a doctor’s prescription and dispensed by a compounding pharmacy.
